ATE374602T1 - Orale kapselformulierung mit verbesserter physikalischer stabilität - Google Patents

Orale kapselformulierung mit verbesserter physikalischer stabilität

Info

Publication number
ATE374602T1
ATE374602T1 AT02799287T AT02799287T ATE374602T1 AT E374602 T1 ATE374602 T1 AT E374602T1 AT 02799287 T AT02799287 T AT 02799287T AT 02799287 T AT02799287 T AT 02799287T AT E374602 T1 ATE374602 T1 AT E374602T1
Authority
AT
Austria
Prior art keywords
physical stability
improved physical
capsule formulation
oral capsule
capsule
Prior art date
Application number
AT02799287T
Other languages
English (en)
Inventor
Amir Shojaei
Scott Ibrahim
Beth Burnside
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE374602T1 publication Critical patent/ATE374602T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02799287T 2001-12-21 2002-12-20 Orale kapselformulierung mit verbesserter physikalischer stabilität ATE374602T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34243001P 2001-12-21 2001-12-21
US10/324,954 US7011846B2 (en) 2001-12-21 2002-12-20 Oral capsule formulation with increased physical stability

Publications (1)

Publication Number Publication Date
ATE374602T1 true ATE374602T1 (de) 2007-10-15

Family

ID=26984706

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02799287T ATE374602T1 (de) 2001-12-21 2002-12-20 Orale kapselformulierung mit verbesserter physikalischer stabilität

Country Status (9)

Country Link
US (1) US7011846B2 (de)
EP (1) EP1455763B1 (de)
JP (1) JP2005531495A (de)
AT (1) ATE374602T1 (de)
AU (1) AU2002364212B2 (de)
CA (1) CA2466868C (de)
DE (1) DE60222803T2 (de)
ES (1) ES2294197T3 (de)
WO (1) WO2003055468A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030048026A (ko) * 2001-07-06 2003-06-18 펜웨스트 파머슈티칼즈 컴파니 옥시모르폰의 서방형 제제
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP4694207B2 (ja) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US8557291B2 (en) 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
PT1765292T (pt) 2004-06-12 2017-12-29 Collegium Pharmaceutical Inc Formulações de fármacos dissuasoras de abuso
AU2006206399B2 (en) * 2005-01-20 2012-04-05 University Of Rochester Compositions and methods relating to mitochondrial hyperpolarization in neurological disease
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
GB0523041D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
ATE464881T1 (de) 2006-04-13 2010-05-15 Riemser Specialty Production Gmbh Partialglyceride als schmiermittel für pharmazeutische zusammensetzungen enthaltend thienoä3,2-cüpyridin-derivate
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2690490C (en) * 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
US9468638B2 (en) * 2010-09-24 2016-10-18 Texas Southern University Itraconazole formulations
US9622981B2 (en) 2011-11-17 2017-04-18 Mylan Inc. Liquid-filled hard gel capsule pharmaceutical formulations
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
EP2875359A4 (de) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science Zusammensetzungen und verfahren zur behandlung oder prävention von stoffwechselsyndromerkrankungen
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN121177244A (zh) 2016-05-25 2025-12-23 技源集团股份有限公司 包含3-羟基-3-甲基丁酸的软凝胶胶囊剂
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN118078771B (zh) * 2024-04-07 2024-09-27 广东润科生物科技有限公司 降血脂软胶囊及其生产工艺

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2906603A1 (de) * 1979-02-21 1980-09-04 Boehringer Mannheim Gmbh N-substituierte aziridin-2-carbonsaeurederivate, verfahren zu deren herstellung sowie diese substanzen enthaltende arzneimittel
US4339428A (en) * 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
IE61651B1 (en) * 1990-07-04 1994-11-16 Zambon Spa Programmed release oral solid pharmaceutical dosage form
US5431916A (en) * 1993-04-29 1995-07-11 The Procter & Gamble Company Pharmaceutical compositions and process of manufacture thereof
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
FR2737121B1 (fr) * 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
US5776957A (en) * 1996-11-15 1998-07-07 The University Of Kentucky Research Foundation Nornicotine enantiomers for use as a treatment for dopamine related conditions and disease states
GB9724544D0 (en) * 1997-11-21 1998-01-21 Smithkline Beecham Plc Novel Formulation
US20020032220A1 (en) * 1997-11-21 2002-03-14 Smithkline Beecham Plc Formulations comprising dissolved paroxetine
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
ATE290372T1 (de) * 2000-07-24 2005-03-15 Upjohn Co Selbstemulgierendes system zur abgabe von sehr wasserunlöslichen und lipophilen arzneimitteln

Also Published As

Publication number Publication date
DE60222803T2 (de) 2008-07-17
AU2002364212B2 (en) 2007-09-20
EP1455763A4 (de) 2006-01-18
EP1455763B1 (de) 2007-10-03
WO2003055468A1 (en) 2003-07-10
CA2466868A1 (en) 2003-07-10
US7011846B2 (en) 2006-03-14
ES2294197T3 (es) 2008-04-01
CA2466868C (en) 2010-06-22
JP2005531495A (ja) 2005-10-20
AU2002364212A1 (en) 2003-07-15
DE60222803D1 (de) 2007-11-15
US20030124182A1 (en) 2003-07-03
EP1455763A1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
ATE374602T1 (de) Orale kapselformulierung mit verbesserter physikalischer stabilität
PT750495E (pt) Utilizacao de um surfactante lipofilico numa composicao farmaceutica
NO20000467L (no) Farmasøytisk preparat i form av en selvemulgerende formulering for lipofile forbindelser
EE200300235A (et) Ravimpreparaat, milles aktiivne ingredient on ühtlaselt dispergeeritud abiainete alussegus, ning seda sisaldav doseerimisvorm
EP1337249A4 (de) Zusammensetzungen und verfahren zur verabreichung von pharmakologisch aktiven verbindungen
ES2110377T1 (es) Formulacion galenica de fenofibrato y aplicacion de la misma.
HK40583A (en) Nifedipine-containing solid preparation composition
DK1920764T3 (da) Fluprostenolisopropylester til anvendelse i behandling af glaukom og okulær hypertension
CO4940469A1 (es) Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol
MX373796B (es) Composición de solubilización farmacéuticamente aceptable y forma de dosificación farmacéutica que contiene la misma.
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
LV11884A (lv) Ciklosporina oralas arstnieciskas formas ar augstu biopieejamibu
WO2001074331A1 (en) Oily compositions containing highly fat-soluble drugs
DK1173153T3 (da) Orale farmaceutiske præparater, som indeholder langkædede triglycerider og lipofile overfladeaktive midler
BR0209283A (pt) Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
DE69421366D1 (de) Staurosporinderivate und Polyalkylenglykol-Glyceride enthaltende Arzneimittel
PT92647A (pt) Processo para a preparacao de 5-cloro-2-< { (3,4-dimetoxi-2-piridinil)-metil}-sulfinil>-1h-benzimidazol e de composicoes farmaceuticas que o contem
YU17899A (sh) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
IT1284604B1 (it) Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
DE69325236D1 (de) Pharmazeutische Zusammensetzungen enthaltend Urodeoxycholicsäure
PE10396A1 (es) Formulacion farmaceutica administrada oralmente
RU98113920A (ru) Производные олигопептидов, содержащие d-алкилтриптофан и способные активировать высвобождение гормона роста
DK1009380T3 (da) Fremgangsmåde til fremstilling af farmaceutiske formuleringer
WO2002011709A3 (de) Pharmazeutische, ramipril enthaltende brauseformulierung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties